High ambient glucose levels modulates the production of MMP-9 and α5(IV) collagen by cultured podocytes

Cellular Physiology and Biochemistry

Volumn 17, Issue 1-2, 2006, Pages 57-68

  Bai, Yaling ^a,b   Wang, Lizhu ^a   Li, Yongqiang ^a   Liu, Senyan ^a   Li, Jingzi ^a   Wang, Haiyan ^a   Huang, Haichang ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Extracellular matrix; Glomerular epithelial cells; Glomerular filtration barrier; Glomerulosclerosis

Indexed keywords

COLLAGEN TYPE 4; GELATIN; GELATINASE A; GELATINASE B; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR ETS 1;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; INCUBATION TIME; LONG TERM EXPOSURE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; STATISTICAL SIGNIFICANCE;

ANIMALIA; MURINAE;

EID: 33644995630     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091464     Document Type: Article

References (43)

1. Caramori ML, Mauer M: Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003;12:273-282.
2. Phillips A, Janssen U, Floege J: Progression of diabetic nephropathy. Insights from cell culture studies and animal models. Kidney Blood Press Res 1999;22:81-97.
3. Hoshi S, Shu Y, Yoshida F, Inagaki T, Sonoda J, Watanabe T, Nomoto K, Nagata M: Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab Invest 2002;82:25-35.
4. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162:1123-1137
5. Gross ML, Ritz E, Schoof A, Adamczak M, Koch A, Tulp O, Parkman A, El-Shakmak A, Szabo A, Amann K: Comparison of renal morphology in the Streptozotocin and the SHR/N-cp models of diabetes. Lab Invest 2004;84:452-454.
6. White KE, Bilous RW, Diabiopsies Study Group: Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant 2004;19:1437-1440.
7. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-853
8. Phillips CA, Molitch ME: The relationship between glucose control and the development and progression of diabetic nephropathy. Curr Diab Rep 2002;2:523-529.
9. Strippoli GF, Di Paolo S, Cincione R, Di Palma AM, Teutonico A, Grandaliano G, Schena FP, Gesualdo L: Clinic and therapeutic aspects of diabetic nephropathy. J Nephrol 2003;16:487-499.
10. Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper ME, Wilkinson-Berka JL, Gilbert RE: Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001;44:878-882
11. Gross ML, El-Shakmak A, Szabo A, Koch A, Kuhlmann A, Munter K, Ritz E, Amann K: ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003;46:856-868.
12. McLennan SV, Fisher E, Martell SY, Death AK, Williams PF, Lyons JG, Yue DK: Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: Possible role in diabetic nephropathy. Kidney Int Suppl 2000;77:S81-S87.
13. Watanabe K, Kinoshita S, Nakagawa H: Gelatinase secretion by glomerular epithelial cells. Nephron 1990;56:405-409.
14. Knowlden J, Martin J, Davies M, Williams JD: Metalloproteinase generation by human glomerular epithelial cells. Kidney Int 1995;47:1682-1689.
15. Martin J, Steadman R, Knowlden J, Williams J, Davies M: Differential regulation of matrix metalloproteinases and their inhibitors in human glomerular epithelial cells in vitro. J Am Soc Nephrol 1998;9:1629-1637.
16. Asanuma K, Shirato I, Ishidoh K, Kominami E, Tomino Y: Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes. Kidney Int 2002;62:822-831.
17. Nagase H, Woessner JF Jr: Matrix metalloproteinases. J Biol Chem 1999;274:21491-21494.
18. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, Kriz W, Zeller R: Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997;236:248-258.
19. McLennan SV, Fisher EJ, Yue DK, Turtle JR: High glucose concentration causes a decrease in mesangium degradation. A factor in the pathogenesis of diabetic nephropathy. Diabetes 1994;43:1041-1045.
20. Artishevsky A, Cha DR, Adler S, Nast CC, Feld S, Glassock RJ, Adler SG: The effect of transfection of antisense cDNA for procollagen alpha 1 (IV) on stimulated proliferation in rat glomerular endothelial cells. J Am Soc Nephrol 1997;8:61-69.
21. Wang S, Hirschberg R: Bone Morphogenetic Protein-7 Signals Opposing Transforming Growth Factor β in Mesangial Cells. J Biol Chem 2004;279: 23200-23206.
22. Tanaka H, Hojo K, Yoshida H, Yoshioka T, Sugita K: Molecular cloning and expression of the mouse 105-kDa gelatinase cDNA. Biochem Biophys Res Comm 1993;190:732-740.
23. Baricos WH, Shah SV: Proteolytic enzymes as mediators of glomerular injury. Kidney Int 1991;40:161-173.
24. Lovett DH, Sterzel RB, Kashgarian M, Ryan JL: Neutral proteinase activity produced in vitro by cells of the glomerular mesangium. Kidney Int 1983;23:342-349.
25. Piedagnel R, Murphy G, Ronco PM, Lelongt B: Matrix metalloproteinase 2 (MMP2) and MMP9 are produced by kidney collecting duct principal cells but are differentially regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor.J Biol Chem 1999;274:1614-1620.
26. Martin J, Steadman R, Knowlden J, Williams J, Davies M: Differential regulation of matrix metalloproteinases and their inhibitors in human glomerular epithelial cells in vitro. J Am Soc Nephrol 1998;9:1629-1637.
27. Mudge SJ, Paizis K, Auwardt RB, Thomas RJ, Power DA: Activation of nuclear factor-kappa B by podocytes in the autologous phase of passive Heymann nephritis. Kidney Int 2001;59:923-931.
28. Ebihara I, Nakamura T, Shimada N, Koide H: Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus.Am J Kidney Dis 1998;32:544-550.
29. Diamant M, Hanemaaijer R, Verheijen JH, Smit JW, Radder JK, Lemkes HH: Elevated matrix metalloproteinase-2 and -9 in urine, but not in serum, are markers of type 1 diabetic nephropathy. Diabetic Med 2001;18:423-426.
30. Tashiro K, Koyanagi I, Ohara I, Ito T, Saitoh A, Horikoshi S, Tomino Y: Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 2004;18:206-210.
31. Lenz O, Elliot SJ, Stetler-Stevenson WG: Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol 2000;11:574-581.
32. Schaefer L, Han X, August C, Matzkies F, Lorenz T, Schaefer RM: Differential regulation of glomerular gelatinase B (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in obese Zucker rats. Diabetologia 1997;40:1035-1043.
33. McLennan SV, Kelly DJ, Cox AJ, Cao Z, Lyons JG, Yue DK, Gilbert RE: Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases .Diabetologia 2002;45:268-275.
34. Kikkawa R, Koya D, Haneda M: Progression of diabetic nephropathy. Am J Kidney Dis 2003;41:S19-S21.
35. Igarashi M, Wakasaki H, Takahara N, Ishii H, Jiang ZY, Yamauchi T, Kuboki K, Meier M, Rhodes CJ, King GL: Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 1999;103:185-185.
36. Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R: Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 1997;46:847-853.
37. Tomlinson DR: Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabetologia 1999;42:1271-1281.
38. Tsang KJ, Crowe DL: Retinoic acid and extracellular matrix inhibition of matrix mettalloproeinase 9 expression is mediated by the mitogen actiated protein kinase pathway. Int J Oncol 2001;18:369-374.
39. Cho A, Graves J, Reidy MA: Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000;20:2527-2532.
40. Eberhardt W, Schulze M, Engels C, Klasmeier E, Pfeilschifter J: Glucocorticoid-mediated suppression of cytokine-induced matrix metalloproteinase-9 expression in rat mesangial cells: involvement of nuclear factor-kappaB and Ets transcription factors. Mol Endocrinol 2002;16:1752-1766.
41. Nakamura Y, Esnault S, Maeda T, Kelly EA, Malter JS, Jarjour NN: Ets-1 regulates TNF-alpha-induced matrix metalloproteinase-9 and tenascin expression in primary bronchial fibroblasts. J Immunol 2004;172:1945-1952.
42. Senyan Liu, Yan Liang, Haichang Huang, Lizhu Wang, Yongqiang Li, Jingzi Li, Xiaomei Li, Haiyan Wang: ERK-dependent Signaling Pathway and Transcriptional Factor Ets-1 Regulate Matrix Metalloproteinase-9 Production in Transforming Growth Factor-β1 Stimulated Glomerular Podocytes. Cell Physiol Biochem 2005;16:207-216.
43. Ito H, Duxbury M, Benoit E, Clancy TE, Zinner MJ, Ashley SW, Whang EE: Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res 2004;64:7439-7446.